Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $467.35. The company's market cap stands at 118.6B, with a P/E ratio of 32.94.
As of 2026-01-23, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $458.94 and $472.58. The current price stands at $467.35, placing the stock +1.8% above today's low and -1.1% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.51M, compared to an average daily volume of 1.67M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Vertex Pharmaceuticals (VRTX)’ povetacicept was granted FDA orphan designation as a treatment of membranous nephropathy, according to a post to the agency’s web...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesd...
Recent analyst moves have put Vertex Pharmaceuticals (VRTX) back in focus, with Bernstein upgrading the stock and UBS initiating coverage. Both firms point to c...
Analyst ratings
69%
of 36 ratingsMore VRTX News
These stocks are definitely keepers. Once upon a time, I frequently traded in and out of stocks. However, I began to notice that the stocks I held onto tended...
Vertex Pharmaceuticals recently reported strong 2025 third-quarter results and outlined its 2026 pipeline and business plans, highlighting continued growth in i...